258 related articles for article (PubMed ID: 35356254)
21. Survival outcomes of hepatic resection compared with transarterial chemoembolization or sorafenib for hepatocellular carcinoma with portal vein tumor thrombosis.
Lee JM; Jang BK; Lee YJ; Choi WY; Choi SM; Chung WJ; Hwang JS; Kang KJ; Kim YH; Chauhan AK; Park SY; Tak WY; Kweon YO; Kim BS; Lee CH
Clin Mol Hepatol; 2016 Mar; 22(1):160-7. PubMed ID: 27044767
[TBL] [Abstract][Full Text] [Related]
22. Prognosis of patients with hepatocellular carcinoma and portal vein tumor thrombus treated with combination of transarterial chemoembolization and palliative thermal ablation.
Zhou Q; An Y; Liu T; Liu Z; Li R; Wang C; Zhou F; Liu C; Zhu K
Int J Hyperthermia; 2022; 39(1):97-107. PubMed ID: 34979845
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombus: A Systematic Review and Meta-Analysis.
Deng J; Liao Z; Gao J
Curr Oncol; 2023 Jan; 30(1):1243-1254. PubMed ID: 36661745
[TBL] [Abstract][Full Text] [Related]
24. Comparing the effectiveness and safety of Sorafenib plus TACE with Apatinib plus TACE for treating patients with unresectable hepatocellular carcinoma: a multicentre propensity score matching study.
Yin L; Liu KC; Lv WF; Lu D; Tan YL; Wang GX; Dai JY; Zhu XH; Jiang B
Cancer Imaging; 2023 May; 23(1):52. PubMed ID: 37254146
[TBL] [Abstract][Full Text] [Related]
25. Comparison of the efficacy and safety of Transarterial chemoembolization with and without Apatinib for the treatment of BCLC stage C hepatocellular carcinoma.
Chen S; Yu W; Zhang K; Liu W
BMC Cancer; 2018 Nov; 18(1):1131. PubMed ID: 30453925
[TBL] [Abstract][Full Text] [Related]
26. Sorafenib combined with transarterial chemoembolization versus transarterial chemoembolization alone for advanced-stage hepatocellular carcinoma: a propensity score matching study.
Hu H; Duan Z; Long X; Hertzanu Y; Shi H; Liu S; Yang Z
PLoS One; 2014; 9(5):e96620. PubMed ID: 24817002
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of apatinib in patients with sorafenib-transarterial chemoembolization refractory hepatocellular carcinoma: a retrospective study.
Cao Y; Ouyang T; Xiong F; Kan X; Chen L; Liang B; Zheng C
Hepatol Int; 2021 Oct; 15(5):1268-1277. PubMed ID: 34415515
[TBL] [Abstract][Full Text] [Related]
28. Hepatocellular carcinoma with portal vein tumor thrombus: treatment with transarterial chemoembolization combined with sorafenib--a retrospective controlled study.
Zhu K; Chen J; Lai L; Meng X; Zhou B; Huang W; Cai M; Shan H
Radiology; 2014 Jul; 272(1):284-93. PubMed ID: 24708192
[TBL] [Abstract][Full Text] [Related]
29. Chemoembolization Plus Radiotherapy Versus Chemoembolization Plus Sorafenib for the Treatment of Hepatocellular Carcinoma Invading the Portal Vein: A Propensity Score Matching Analysis.
Chu HH; Kim JH; Shim JH; Yoon SM; Kim PH; Alrashidi I
Cancers (Basel); 2020 Apr; 12(5):. PubMed ID: 32365655
[TBL] [Abstract][Full Text] [Related]
30. Lenvatinib plus drug-eluting bead transarterial chemoembolization with/without hepatic arterial infusion chemotherapy for hepatocellular carcinoma larger than 7 cm with major portal vein tumor thrombosis: a multicenter retrospective cohort study.
Cai M; Liang L; Zhang J; Chen N; Huang W; Guo Y; Hong X; Lin L; Liu Y; Dan C; Deng H; Liu X; Zhou J; Chen Y; Chen H; Zhu K
Int J Surg; 2024 Jun; ():. PubMed ID: 38869974
[TBL] [Abstract][Full Text] [Related]
31. Transarterial chemoembolization plus apatinib with or without camrelizumab for unresected hepatocellular carcinoma: A two-center propensity score matching study.
Zhu D; Ma K; Yang W; Zhou HF; Shi Q; Ren JW; Xie YG; Liu S; Shi HB; Zhou WZ
Front Oncol; 2022; 12():1057560. PubMed ID: 36439471
[TBL] [Abstract][Full Text] [Related]
32. Drug-Eluting Bead Transarterial Chemoembolization versus Conventional Transarterial Chemoembolization Both Combined Apatinib for Hepatocellular Carcinoma: A Retrospective, Propensity-Score Matched Study.
Ouyang T; Liu J; Shi C; Zhu L; Guo X
J Hepatocell Carcinoma; 2021; 8():1459-1471. PubMed ID: 34858890
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of apatinib combined with transarterial chemoembolization for hepatocellular carcinoma with portal venous tumor thrombus: a retrospective study.
Liu C; Xing W; Si T; Yu H; Guo Z
Oncotarget; 2017 Nov; 8(59):100734-100745. PubMed ID: 29246017
[TBL] [Abstract][Full Text] [Related]
34. The Efficacy of Transarterial Chemoembolization plus Apatinib or Sorafenib in the Treatment of Advanced Hepatocellular Carcinoma.
Chen L; Sun T; Wu L; Zhang W; Ren Y; Xiang D; Liang B; Zheng C
J Oncol; 2021; 2021():8169012. PubMed ID: 34840572
[TBL] [Abstract][Full Text] [Related]
35. Gamma knife radiosurgery versus transcatheter arterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a propensity score matching study.
Su K; Gu T; Xu K; Wang J; Liao H; Li X; Wen L; Song Y; Zhong J; He B; Liu X; He J; Liu Y; Li Q; Feng X; Chen S; Yang B; Huang W; Jin H; Luo X; Hu T; Chen J; Wu Z; Lu S; Zhang J; Rao M; Xie Y; Wang J; Zhu X; Chen L; Li B; Su S; Yang X; Wang J; Zeng H; Wang P; Yan M; Chen X; He K; Han Y
Hepatol Int; 2022 Aug; 16(4):858-867. PubMed ID: 35729469
[TBL] [Abstract][Full Text] [Related]
36. Should transarterial chemoembolization be given before or after intensity-modulated radiotherapy to treat patients with hepatocellular carcinoma with portal vein tumor thrombus? a propensity score matching study.
Li X; Guo W; Guo L; Lau WY; Ge N; Wang K; Cheng S
Oncotarget; 2018 May; 9(36):24537-24547. PubMed ID: 29849959
[TBL] [Abstract][Full Text] [Related]
37. Combined endovascular brachytherapy, sorafenib, and transarterial chemobolization therapy for hepatocellular carcinoma patients with portal vein tumor thrombus.
Zhang ZH; Liu QX; Zhang W; Ma JQ; Wang JH; Luo JJ; Liu LX; Yan ZP
World J Gastroenterol; 2017 Nov; 23(43):7735-7745. PubMed ID: 29209114
[TBL] [Abstract][Full Text] [Related]
38. DEM-TACE as the initial treatment could improve the clinical efficacy of the hepatocellular carcinoma with portal vein tumor thrombus: a retrospective controlled study.
Chen J; Lai L; Luo J; Wang H; Li M; Huang M
BMC Cancer; 2022 Nov; 22(1):1242. PubMed ID: 36451104
[TBL] [Abstract][Full Text] [Related]
39. Hepatocellular Carcinoma With Portal Vein Tumor Thrombus Treated With Transarterial Chemoembolization and Sorafenib
Hu HT; Luo JP; Cao GS; Li Z; Jiang M; Guo CY; Yuan H; Yao QJ; Geng X; Park JH; Cheng HT; Jiang L; Ma JL; Zhao Y; Li HL
Front Oncol; 2021; 11():806907. PubMed ID: 35004330
[TBL] [Abstract][Full Text] [Related]
40. Transarterial chemoembolization (TACE) combined with sorafenib versus TACE for hepatocellular carcinoma with portal vein tumor thrombus: a systematic review and meta-analysis.
Zhang X; Wang K; Wang M; Yang G; Ye X; Wu M; Cheng S
Oncotarget; 2017 Apr; 8(17):29416-29427. PubMed ID: 28177886
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
